Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns
ConclusionOur modelling demonstrates that the autumn 2022/spring 2023 booster campaign reduced COVID-19-associated morbidity and mortality. Booster campaigns with alternative eligibility criteria warrant consideration in the UK, given their potential to further reduce morbidity and mortality as future variants emerge. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis
ConclusionOur study presents an overview of the clinical and economic burden of AMR in Japan. Patients with AMR infections experience significantly higher in-hospital mortality, LOS, and direct medical costs compared with patients without AMR infections. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns
ConclusionOur modelling demonstrates that the autumn 2022/spring 2023 booster campaign reduced COVID-19-associated morbidity and mortality. Booster campaigns with alternative eligibility criteria warrant consideration in the UK, given their potential to further reduce morbidity and mortality as future variants emerge. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis
ConclusionOur study presents an overview of the clinical and economic burden of AMR in Japan. Patients with AMR infections experience significantly higher in-hospital mortality, LOS, and direct medical costs compared with patients without AMR infections. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 25, 2024 Category: Infectious Diseases Source Type: research
Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK
ConclusionsThe HZ incidence rate in Europe increased with age and varied across high-risk populations, with high rates for solid organ and stem cell transplants, cancer, and rheumatoid arthritis. Most studies were retrospective with methodological differences affecting generalizability and comparability. Future studies should stratify data by IC population, age, sex, severity, medication, and study timeframe. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 24, 2024 Category: Infectious Diseases Source Type: research
Prognostic Significance of NLR and PLR in COVID-19: A Multi-Cohort Validation Study
ConclusionsConsistent findings across diverse patient populations validate the reliability and applicability of NLR and PLR cut-off values. High NPVs emphasize their role in identifying individuals less likely to experience severe outcomes. These markers not only aid in risk stratification but also guide resource allocation in emergencies or limited-resource situations. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 21, 2024 Category: Infectious Diseases Source Type: research
Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial
ConclusionPotential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV ’s effect on attention and processing speed is, at least partially, mediated by reactive inhibition.Trial RegistrationClinicaltrials.gov identifier [NCT02308332]. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 20, 2024 Category: Infectious Diseases Source Type: research
Fungal Prosthetic Joint Infection: A Case Series and Review of the Literature
ConclusionsTwo-stage revision with extended antifungal therapy is preferred in these infections due to higher rates of positive outcomes. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 13, 2024 Category: Infectious Diseases Source Type: research
Ritonavir: 25 Years ’ Experience of Concomitant Medication Management. A Narrative Review
AbstractRitonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability of concomitantly administered antivirals. Decades of experience with ritonavir-enhanced HIV therapies and, more recently, COVID-19 therapies demonstrate that boosting doses of ritonavir are well tolerated, with an established safety profile. The mechanisms of PK enhancement by ritonavir result in the potential for drug –drug interactions (DDIs) with several classes of drugs, thus making co-medication management an important considerat...
Source: Infectious Diseases and Therapy - April 12, 2024 Category: Infectious Diseases Source Type: research
